Real-time enrollment status for this transfusion-dependent alpha-thalassemia clinical trial
Current Status
Recruiting
Checked: August 31, 2026 at 6:33 PM UTC
| NCT Number | NCT07506863 |
| Recruiting Status | Recruiting |
| Condition | Transfusion-dependent Alpha-Thalassemia |
| Phase | PHASE3 |
| Target Enrollment | 54 participants |
| Active Locations | 3 sites in the US |
| Sponsor | Agios Pharmaceuticals, Inc. |
| Last Updated on CT.gov | August 27, 2026 (4 days ago) |
As of August 31, 2026: Clinical trial NCT07506863 is currently recruiting participants. This phase3 study for transfusion-dependent alpha-thalassemia is actively seeking new participants at 3 locations across the United States. The study is sponsored by Agios Pharmaceuticals, Inc.. This status information is automatically verified from the official ClinicalTrials.gov registry.
Yes, NCT07506863 is actively recruiting participants as of August 31, 2026. You can check eligibility and apply through HelloStudys.
This trial is recruiting at 3 locations in the United States. View all available locations on the full study page.
Check your eligibility and express interest by completing the application form on the study page. A research coordinator will follow up to discuss next steps.
The official ClinicalTrials.gov record for NCT07506863 was last updated 4 days ago (August 27, 2026). HelloStudys verifies this status automatically.